Tamibarotene
As of the edition of 20 October 2026, Tamibarotene is a small molecule: stopped in 2024; acts on RARA and RARB.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Small molecule
- Registered trials
- 12, 5 stopped early
- Disease areas
- Cancer; Blood and lymph; Digestive system; Pregnancy and women's health; Urinary and reproductive; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 9 | 3 | 1 | 3 |
| Phase 3 | 2 | 0 | 0 | 1 |
| All trials | 12 |